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SUMMARY 
The role of opioids in endocrine regulation has been the subject of numerous studies. Surprisingly, 
however, the acute endocrine effects of morphine on basal hormonal levels it{ man have not been 
adequately documented. We report here the effects of intravenous morphine (5 mg) on plasma 
cortisol and prolactin. Fourteen healthy volunteers (nine male, five female) received morphine at 
0930 hr. Blood samples were collected immediately before and 30, 60, 90, 120 and 180 min after 
the injection. In six of the male subjects the procedure was repeated with a placebo (normal saline) 
injection. Morphine stimulated prolactin release. There was a trend for a greater response in 
females compared to male subjects. Cortisol secretion was markedly suppressed by morphine. In 
sharp contrast to the results obtained with placebo, cortisol levels following morphine declined 
progressively at a rate consistent with the half-life of cortisol. This downward trend of cortisol 
values continued uninterrupted for the duration of the experiment in all 14 subjects. These results 
are consistent with the presence of an inhibitory opioid mechanism in the human hypothalamo- 
pituitary - adrenal axis. 
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INTRODUCTION 
SINCE the discovery of the opiate receptors and endogenous opioid ligands the role of 
opioids in endocrine regulation has been the subject of numerous investigations. In man 
most of the evidence is consistent with an inhibitory opioid effect on hypothalamic- 
pituitary- adrenal function (Morley, 1981). This, however, conflicts with the stimulatory 
effect of the prototypical opiate alkaloid, morphine, on the hypothalamic-pituitary- 
adrenal system of the experimental animal (Meites et al., 1979). Although dosage and/or 
species differences could account for the discrepancy, the acute effect of morphine on this 
system in man is in fact poorly documented (Cushman, 1981). We were able to locate only 
two reports of controlled studies on the acute effect of morphine on human basal 
hormonal levels. Tolls et  al. (1975) reported increased prolactin secretion but no effect on 
cortisol for 2 hr following the intravenous administration of morphine (10 mg), whereas 
McDonald et  al. (1959) found a mid-day suppression of cortisol 4 and 5 hr after the 
subcutaneous administration of morphine (16 mg). We now report data indicating clearly 
that the intravenous administration of morphine (5 mg) inhibits cortisol secretion. 
MATERIALS AND METHODS 
Fourteen informed, consenting, healthy volunteers, nine men and five women, 23 -  38 yr old were studied. 
None were receiving medications. The women were studied between days three and five of their menstrual cycle. 
After an overnight fast they remained supine in bed from 0730 hr until completion of the study. An indwelling 
catheter was inserted in the antecubital vein at 0830 hr and maintained open by a slow infusion of heparinized 
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normal  saline. Morphine sulfate (5 mg in 1 ml) was injected through the same catheter over 1 min at 0930 hr. In 
six male subjects the procedure was repeated using a placebo injection (normal saline). At least 48 hr elapsed 
between studies, and subjects were blind to the sequence. Blood samples were obtained immediately before and 
30, 60, 90, 120 and 180 min after the injection. 
Blood was collected in heparinized tubes and immediately centrifuged. P lasma samples were frozen and stored 
at - 2 0 ° C .  Total plasma corticoids ( 'cortisol ') were measured by the transcortin method of Murphy (1967). 
Intra- and interassay coefficients of  variation were 3.9 and 10.8°70 respectively. P lasma prolactin was measured 
by RIA using antibody and standard donated by the National Hormone  and Pituitary Program. Intra- and 
interassay coefficients of  variation were 5.4 and 6.807o respectively. All plasma samples from a single subject 
were analyzed in duplicate in the same assay. 
Data were analyzed using repeated measures analysis of  variance. 
RESULTS 
The effect of morphine on prolactin secretion is illustrated in Fig. I. Morphine 
stimulated prolactin secretion in both male (df = 5,40; F = 3.57; p < 0.01) and female 
(df -- 5,20; F = 7.91; p < 0.001) subjects. In contrast, prolactin levels did not change 
with time following the placebo injection (df = 5,25; F --- 0.36; p = N.S.). There was no 
difference in the prolactin response to morphine between male and female subjects (df = 
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FIG. 1. Prolactin response to morphine in nine male • • and five female-• - • subjects and to placebo in 
six male subjects © ©. Data represent mean ± S.E.M. 
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The effect of  morphine on cortisol secretion is shown in Fig. 2. Following morphine,  
plasma cortisol levels declined progressively in both male ( d f  = 5,40; F = 38.98; 
p < 0.001) and female ( d f  = 5,20; F = 19.84; p < 0.001) subjects. There was no 
difference in the cortisol response to morphine between male and female subjects ( d f  = 







FIG. 2. Cortisol response to morphine in nine male • 
six male subjects (3 
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= and five female • • subjects and to placebo in 
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DISCUSSION 
The data show that the intravenous administration of  5 mg morphine stimulates 
prolactin and inhibits cortisol secretion. The observed effect on prolactin secretion is in 
agreement with an earlier report  by Tolis et al. (1975). It is also consistent with the 
stimulation of  prolactin secretion produced by B-endorphin, enkephalin analogues and 
other opioid peptides (Catlin et al., 1980; von Graffenfr ied et al., 1978; Stubbs et ai., 
1978; Degli Uberti et al., 1983). In our experiment, the sequence of  the study for the six 
male subjects receiving both morphine and placebo was morphine followed by placebo. It  
is unlikely that the observed increment in prolactin release was a non-specific anticipatory 
or stress effect, since cortisol levels decreased concomitantly.  
Compared  to men, women exhibit a greater prolactin response to various stimuli, a 
difference possibly related to the presence of  higher estrogen levels in women (Degli 
Uberti  et al., 1983; Bowers et al., 1971; Judd et al., 1976; Carlson et al., 1973). A trend in 
this direction was observed in the present study. Failure to obtain statistical significance 
could be attributed to number  of  subjects studied and /o r  the fact that our females were 
studied during the early follicular phase of  their menstrual cycle which is characterized by 
lower estrogen levels. 
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The plateau of cortisol values seen after placebo is in agreement with the observations 
of Weitzman et  al. (1971). Using 20 min sampling they documented the continuous 
presence of intermittent cortisol rises during this part of the day. Since these individual 
secretory episodes occur irregularly, the fluctuation in plasma cortisol is not represented 
in the mean values, which appeared to plateau from 1100 hr, 3 hr following 'lights on' 
time. Our time of morphine administration (0930 hr) was also 3 hr after waking. 
In contrast to the plateau following placebo, plasma cortisol levels declined 
progressively after the injection of morphine, at a rate consistent with the half-life of 
cortisol (Weitzman et al., 1971; Peterson & Wyngaarden, 1956). Cortisol values continued 
to decline for the duration of the experiment in all 14 subjects studied. These data clearly 
indicate that in man morphine suppresses cortisol secretion, an observation consistent 
with the reported effects of methadone, enkephalin analogues and opiate addiction and 
withdrawal (Gold et al., 1980; Stubbs et al., 1978; Del Pozo et al., 1980; Eisenman et al., 
1961). These data are also in agreement with the reported increases in ACTH and cortisol 
following the administration of the opiate antagonist, naloxone (Volavka et al., 1979; 
Morley et al., 1980; Grossman et al., 1982). 
Our results differ from those of Tolis et al. (1975), who reported no effect of morphine 
on cortisol. This discrepancy could be attributed to dose and subject differences. We used 
a lower dose of morphine. Furthermore, our healthy volunteers served as their own 
controls whereas in their study morphine and placebo were administered to different 
subjects admitted for elective surgery. Our results are also at variance with those of 
McDonald et  al. 0959), who did not detect an effect until 4 and 5 hr following the 
administration of morphine. Differences in dose, route of administration and sampling 
frequency (they used only hourly samples) could account for their failure to detect an 
earlier effect. 
Morphine could act to decrease plasma cortisol at a number of levels within the 
hypothalamo- pituitary- adrenal system. Under certain conditions and at high 
concentrations, certain exogenous opioids can decrease steroidogenesis in adrenal cells in 
vitro (Gibson et  al., 1979; R~tcz et al., 1980; Diel et al., 1981). The relevance of these 
observations to the present data, however, is uncertain. Although we did not measure 
ACTH, we believe the effect not to be in the adrenals, since the adrenal cortex of acutely 
morphinized subjects is quite responsive to ACTH (McDonald et  al., 1959). Whether 
morphine exerts an effect directly on the pituitary or acts via the hypothalamus and the 
limbic system remains to be determined. 
We thank R. Edwards, P. Nelson, .1. Ritchie, and L. Shapiro for their assistance. This study was supported in 
part by NIMH Grant No. MH 28794-07. 
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